Rabisin

Rabisin is a **non-specific brand name** that refers to two distinct marketed drugs. In veterinary medicine, Rabisin is an **inactivated rabies vaccine** developed by Boehringer Ingelheim for active immunization of animals including dogs, cats, cattle, sheep, horses, ferrets, mink, and polecats to reduce mortality and clinical signs caused by rabies virus infection. This product is a **biologic vaccine** based on **inactivated rabies virus G52 strain** and is formulated with **aluminum hydroxide** as adjuvant. In human medicine, Rabisin is also used as a brand name for **rabeprazole sodium**, a **small-molecule proton pump inhibitor** that suppresses gastric acid secretion by irreversibly inhibiting the gastric **H+/K+-ATPase** at the secretory surface of parietal cells, and is used for acid-related disorders such as GERD, peptic ulcer disease, acid reflux, and Zollinger-Ellison syndrome. Because the queried name maps to two different products with different modalities, indications, routes, and species use, the term should be treated as ambiguous unless the veterinary vaccine or the rabeprazole product is explicitly specified.

Brand names

Rabisin